Method for producing PF1378A, protein, nucleic acid, and transformant

By utilizing the protein encoded by the g5141 gene or its variant gene in the biosynthesis process of Aspergillus filamentous fungi to contact PF1378B, the biosynthesis of PF1378A was achieved, solving the problem of chemical synthesis in the prior art and providing an efficient manufacturing method.

CN121464218APending Publication Date: 2026-02-03MITSUI CHEM AGRO INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202480034069.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-21
Publication Date
2026-02-03

AI Technical Summary

Technical Problem

Existing technologies make it difficult to manufacture PF1378A through chemical synthesis methods; it requires biosynthesis through microbial culture.

Method used

In the process of biosynthesizing PF1378A using filamentous Aspergillus fungi, the conversion of PF1378B to PF1378A is achieved by contacting the protein encoded by the g5141 gene or its variant gene with PF1378B, or by carrying out corresponding processes within the microbial cell.

Benefits of technology

An efficient biosynthetic pathway is provided to manufacture PF1378A, solving the problems of chemical synthesis and realizing a highly efficient biosynthetic process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

A method for producing PF1378A, which comprises a step for obtaining PF1378A by bringing one or more proteins selected from the group consisting of the following (1)-(4) into contact with PF1378B: (1) a protein comprising the amino acid sequence depicted in SEQ ID NO: 2, (2) an amino acid sequence having 70% or more sequence homology with respect to the amino acid sequence depicted in SEQ ID NO: 2, and (3) a protein comprising an amino acid sequence having 70% or more sequence homology with respect to the amino acid sequence depicted in SEQ ID NO: 1. (3) a protein encoded by the base sequence depicted in SEQ ID NO: 1; and (4) a protein encoded by a base sequence having a sequence homology of 70% or more with respect to the base sequence depicted in SEQ ID NO: 1, and having an activity of converting PF1378B into PF1378A.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a method for manufacturing PF1378A. More specifically, this invention relates to a method for manufacturing PF1378A, a protein, a nucleic acid, and a transformant. This application claims priority based on Japanese Patent Application No. 2023-084745, filed on May 23, 2023, the contents of which are incorporated herein by reference. Background Technology

[0002] PF1378A ((16-keto Aspergillimide), CAS No.: 199784-50-4) is a compound represented by the following formula (1).

[0003]

[0004] PF1378A has been reported as a metabolite produced by filamentous fungi of the genus *Aspergillus*, and is known to be an anthelmintic active substance against the third instar larvae of *Haemonchus contortus*, a mammalian intestinal parasitic nematode (see, for example, Non-Patent Document 1). Furthermore, Patent Documents 1 and 2 describe PF1378A exhibiting insecticidal activity against agricultural pests such as brown planthoppers. Patent Document 3 describes PF1378A exhibiting insecticidal activity against animal parasitic pests such as ticks and fleas, and demonstrating safety for mammals. Previously, a technique for manufacturing PF1378A using liquid culture was unknown.

[0005] Existing technical documents Patent documents Patent Document 1: International Publication No. 2008 / 156165 Patent Document 2: International Publication No. 2010 / 071218 Patent Document 3: International Publication No. 2010 / 071219 Non-patent literature Non-patent document 1: Banks RM, et al., Novel anthelmintic metabolites from an Aspergillus species; the aspergillimides, The Journal of Antibiotics, 50(10), 840-846, 1997. Summary of the Invention The technical problem that the invention aims to solve Thus, PF1378A is a useful compound, but it is difficult to synthesize chemically and requires biosynthesis through microbial culture or other means. Therefore, elucidating the biosynthetic pathway of PF1378A and applying it to the manufacture of PF1378A is important. The purpose of this invention is to provide a manufacturing technology for PF1378A.

[0006] Technical solutions for solving technical problems The inventors discovered that in the final reaction of PF1378A biosynthesis using Aspergillus filamentous fungi, the protein encoded by the g5141 gene converts PF1378B (Asperparaline A, CAS number: 195966-93-9) into PF1378A, thus completing this invention. The g5141 gene and the protein encoded by the g5141 gene are novel genes and novel proteins discovered by the inventors. PF1378B is a compound represented by the following formula (2).

[0007]

[0008] The inventors further discovered that during the biosynthesis of PF1378B using filamentous Aspergillus fungi, the protein encoded by the g5151a gene converts PF1378C (Asperparaline B, CAS number: 227598-73-4) into PF1378B. The g5151a gene and the protein encoded by the g5151a gene are novel genes and novel proteins discovered by the inventors. PF1378C is a compound represented by the following formula (3).

[0009]

[0010] The present invention includes the following methods.

[0011] [1] A manufacturing method, which is a method for manufacturing PF1378A, includes step (a) of contacting one or more proteins selected from the group consisting of (1) to (4) below with PF1378B to obtain PF1378A.

[0012] (1) A protein composed of the amino acid sequence recorded in sequence number 2, (2) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 2, and having the activity of converting PF1378B to PF1378A. (3) The protein encoded by the base sequence recorded in sequence number 1, (4) A protein encoded by a base sequence having more than 70% sequence homology with the base sequence described in sequence number 1 and having the activity of converting PF1378B to PF1378A.

[0013] [2] According to the manufacturing method described in [1], wherein the above-mentioned step (a) is carried out inside the cells of microorganisms.

[0014] [3] According to the manufacturing method described in [1] or [2], wherein, prior to step (a), a step (b) is further included in which one or more proteins selected from the group consisting of (5) to (8) below are contacted with PF1378C to obtain PF1378B.

[0015] (5) Proteins composed of the amino acid sequence recorded in sequence number 7, (6) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 7, and having the activity of converting PF1378C to PF1378B. (7) The protein encoded by the base sequence recorded in sequence number 6, (8) A protein encoded by a base sequence having more than 70% sequence homology with the base sequence described in sequence number 6 and having the activity of converting PF1378C to PF1378B.

[0016] [4] According to the manufacturing method described in [3], wherein the above-mentioned step (b) is carried out inside the cells of microorganisms.

[0017] [5] A protein comprising the amino acid sequence described in Serial No. 2, or comprising an amino acid sequence having more than 70% sequence homology with respect to the amino acid sequence described in Serial No. 2, and having the activity of converting PF1378B to PF1378A.

[0018] [6] A protein comprising the amino acid sequence described in Serial No. 7, or comprising an amino acid sequence having more than 70% sequence homology with respect to the amino acid sequence described in Serial No. 7, and having the activity of converting PF1378C to PF1378B.

[0019] [7] A nucleic acid that encodes the protein described in [5].

[0020] [8] The nucleic acid according to [7] is composed of the base sequence recorded in sequence number 1, or is composed of a base sequence having more than 70% sequence homology with the base sequence recorded in sequence number 1, and encodes a protein having the activity of converting PF1378B to PF1378A.

[0021] [9] A nucleic acid that encodes the protein described in [6].

[0022]

[10] The nucleic acid according to [9] is composed of the base sequence recorded in sequence number 6, or is composed of a base sequence having more than 70% sequence homology with the base sequence recorded in sequence number 6, and encodes a protein having the activity of converting PF1378C to PF1378B.

[0023]

[11] A transformant having the nucleic acid described in [7] or [8].

[0024]

[12] A transformant having the nucleic acid described in [9] or

[10] .

[0025] The present invention may also include the following methods.

[0026] [P1] A manufacturing method for PF1378A includes a step of contacting a protein encoded by a g5141 gene or a variant of the g5141 gene with PF1378B to obtain PF1378A, wherein the cDNA of the g5141 gene has the base sequence described in Serial No. 1, the cDNA of the variant of the g5141 gene has a base sequence with more than 70% sequence homology to the base sequence described in Serial No. 1, and the protein encoded by the variant of the g5141 gene has the activity of converting PF1378B to PF1378A.

[0027] [P2] The manufacturing method described in [P1] is wherein the above-mentioned process is carried out inside the cells of microorganisms.

[0028] [P3] A nucleic acid that encodes the g5141 gene or a variant thereof, wherein the cDNA of the g5141 gene has the base sequence described in Serial No. 1, the cDNA of the variant gene has a base sequence that has more than 70% sequence homology with the base sequence described in Serial No. 1, and the protein encoded by the variant gene has the activity of converting PF1378B to PF1378A.

[0029] [P4] A transformant containing the nucleic acid described in [P3].

[0030] Invention Effects According to the present invention, a manufacturing technique for PF1378A can be provided. Detailed Implementation

[0031] [Manufacturing method of PF1378A] In one embodiment, the present invention provides a manufacturing method for PF1378A, comprising step (a) of contacting one or more proteins selected from the group consisting of (1) to (4) below with PF1378B to obtain PF1378A.

[0032] (1) A protein composed of the amino acid sequence recorded in sequence number 2, (2) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 2, and having the activity of converting PF1378B to PF1378A. (3) The protein encoded by the base sequence recorded in sequence number 1, (4) A protein encoded by a base sequence having more than 70% sequence homology with the base sequence described in sequence number 1 and having the activity of converting PF1378B to PF1378A.

[0033] In one embodiment, the manufacturing method includes a step (a) of contacting a protein encoded by the g5141 gene or a variant of the g5141 gene with PF1378B to obtain PF1378A, wherein the cDNA of the g5141 gene has the base sequence described in Serial No. 1, the cDNA of the variant gene has a base sequence having more than 70% sequence homology with the base sequence described in Serial No. 1, and the protein encoded by the variant gene has the activity of converting PF1378B to PF1378A.

[0034] In the embodiments, as shown below, the inventors clarified that in the final reaction of the biosynthesis of PF1378A using *Aspergillus aculeatinus* strain PF1378 (hereinafter, sometimes referred to as "Aspergillus PF1378"), the protein encoded by the g5141 gene converts PF1378B into PF1378A. Therefore, PF1378A can be produced by contacting the protein encoded by the g5141 gene or a variant thereof with PF1378B. The base sequence of the cDNA of the g5141 gene from *Aspergillus aculeatinus* PF1378 is shown in Serial No. 1. The amino acid sequence of the protein encoded by the g5141 gene is shown in Serial No. 2. The base sequence of the genomic DNA of the g5141 gene is shown in Serial No. 3.

[0035] In the manufacturing method of this embodiment, the protein composed of the amino acid sequence described in Serial No. 2 may also contain variations as long as it can convert PF1378B to PF1378A. Examples of variations include the deletion, insertion, substitution, or addition of one or more amino acids. Examples of one or more amino acids include 1 to 150, 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, and 1 to 3.

[0036] Examples of variant proteins that are amino acid sequences described in Serial No. 2 include amino acid sequences that are 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology to the amino acid sequence described in Serial No. 2, and that have the activity of converting PF1378B to PF1378A.

[0037] The sequence homology of amino acid sequences can be calculated using methods known to those skilled in the art, such as using Blastp (protein-protein BLAST), a BLAST (Basic Local Alignment Search Tool) retrieval program.

[0038] Alternatively, the sequence homology of the target amino acid sequence relative to the reference amino acid sequence can be determined, for example, as follows. First, the reference amino acid sequence and the target amino acid sequence are aligned. Intervals may be included in each amino acid sequence to maximize sequence homology. Then, the number of identical amino acids in the reference and target amino acid sequences is calculated, and the sequence homology can be determined using the following formula (F2). Sequence homology (%) = Number of identical amino acids / Total number of amino acids in the target amino acid sequence × 100 (F2) The g5141 gene can also contain variations as long as it can convert PF1378B to PF1378A. Examples of variations include deletions, insertions, substitutions, and additions of one or more bases. Examples of "one or more" variations include 1–500, 1–400, 1–300, 1–200, 1–100, 1–50, 1–30, 1–20, 1–10, 1–5, and 1–3 bases. Examples of variant genes of the g5141 gene are genes whose cDNA containing the variant gene has a base sequence that is 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology to the base sequence described in Serial Number 1, and whose protein encodes the protein that has the activity of converting PF1378B to PF1378A.

[0039] Sequence homology of base sequences can be calculated using methods known to those skilled in the art, such as using Blastn (nucleotide-nucleotide BLAST), a BLAST (Basic Local Alignment Search Tool) retrieval program.

[0040] Alternatively, the sequence homology of the target base sequence relative to the reference base sequence can be determined, for example, as follows: First, the reference base sequence and the target base sequence are aligned. Intervals may be included in each base sequence to maximize sequence homology. Then, the number of identical bases in the reference and target base sequences is calculated, and the sequence homology can be determined using the following equation (F1).

[0041] Sequence homology (%) = Number of identical bases / Total number of bases in the target sequence × 100 (F1) Outside the region encoding the active domain, variants of the g5141 gene may have low sequence homology relative to the g5141 gene. The active domain refers to the domain in the protein encoded by the g5141 gene that has the activity of converting PF1378B to PF1378A.

[0042] Based on a comparison of the amino acid sequences of the g5141 gene and its homologs, it is considered that the regions at positions 295–408, 504–707, 1341–1637, 1344–1502, and 1639–1779 of the genomic DNA sequence of the g5141 gene described in Serial Number 3 are well preserved. Therefore, it is believed that the regions at positions 295–408, 504–707, 1341–1637, 1344–1502, and 1639–1779 of the base sequence described in Serial Number 3 are important for the activity of the protein encoded by the g5141 gene. Therefore, the sequence homology of the variant gene of g5141 relative to the g5141 gene is preferably 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, in the regions corresponding to positions 295 to 408, 504 to 707, 1341 to 1637, 1344 to 1502, and 1639 to 1779 in sequence number 3.

[0043] Furthermore, in the variant of the g5141 gene, the sequence homology with respect to the g5141 gene in regions other than those corresponding to positions 295–408, 504–707, 1341–1637, 1344–1502, and 1639–1779 in sequence number 3 can be less than 90%. In this case, the lower limit of sequence homology can be, for example, 50% or more, 60% or more, 70% or more, 75% or more, 80% or more, or 85% or more.

[0044] The variant of the g5141 gene can be a homolog of the g5141 gene in organisms other than Aspergillus niger PF1378, or it can be a g5141 gene or its homolog that has been artificially modified through gene recombination technology. In this specification, genes or proteins with similar base sequences are referred to as homologs.

[0045] In the embodiments, as shown below, the inventors further clarified that during the biosynthesis of PF1378B using *Aspergillus aculeatinus* strain PF1378 (hereinafter, sometimes referred to as "Aspergillus PF1378"), the protein encoded by the g5151a gene converts PF1378C into PF1378B. Therefore, PF1378B can be produced by contacting the protein encoded by the g5151a gene or a variant thereof with PF1378C. The base sequence of the cDNA of the g5151a gene from *Aspergillus aculeatinus* PF1378 is shown in Serial No. 6. The amino acid sequence of the protein encoded by the g5151a gene is shown in Serial No. 7. The base sequence of the genomic DNA of the g5151a gene is shown in Serial No. 8.

[0046] Therefore, the manufacturing method of this embodiment may further include step (b) before the above-described step (a) by contacting one or more proteins selected from the group consisting of (5) to (8) below with PF1378C to obtain PF1378B.

[0047] (5) Proteins composed of the amino acid sequence recorded in sequence number 7, (6) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 7, and having the activity of converting PF1378C to PF1378B. (7) The protein encoded by the base sequence recorded in sequence number 6, (8) A protein encoded by a base sequence having more than 70% sequence homology to the base sequence described in Serial No. 6 and having the activity of converting PF1378C to PF1378B.

[0048] In one embodiment, the manufacturing method may further include a step (b) prior to step (a) of contacting the protein encoded by the g5151a gene or its variant gene with PF1378C to obtain PF1378B. The cDNA of the g5151a gene has the base sequence described in Serial No. 6, the cDNA of the variant gene of the g5151a gene has a base sequence with more than 70% sequence homology to the base sequence described in Serial No. 1, and the protein encoded by the variant gene of the g5151a gene has the activity of converting PF1378C to PF1378B.

[0049] In the manufacturing method of this embodiment, the protein composed of the amino acid sequence described in Serial No. 7 may also contain variations as long as it can convert PF1378C to PF1378B. Examples of variations include the deletion, insertion, substitution, or addition of one or more amino acids. Examples of one or more amino acids include 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, and 1 to 3.

[0050] Examples of variant proteins that are variations of the amino acid sequence described in Serial No. 7 include proteins having an amino acid sequence and the activity of converting PF1378C to PF1378B, wherein the amino acid sequence has 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology with respect to the amino acid sequence described in Serial No. 7. The same applies to sequence homology as described above.

[0051] Similarly, the g5151a gene can also contain variations as long as it can convert PF1378C to PF1378B. Examples of variations include deletions, insertions, substitutions, and additions of one or more bases. Examples of "one or more" variations include 1–300, 1–200, 1–100, 1–50, 1–30, 1–20, 1–10, 1–5, and 1–3 bases. Examples of variant genes of the g5151a gene are genes whose cDNA containing the variant gene has a base sequence with 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology to the base sequence described in Serial Number 6, and whose protein encodes the protein having the activity of converting PF1378C to PF1378B. The same applies to sequence homology as described above.

[0052] In the manufacturing method of this embodiment, PF1378B or PF1378C can be a natural product produced by microorganisms or a substance obtained through chemical synthesis. Furthermore, PF1378B or PF1378C can be an unpurified substance or a purified substance. Purification of PF1378B or PF1378C can be performed alone or in appropriate combinations using common separation methods that utilize its characteristics, such as solvent extraction, ion exchange resin methods, adsorption column chromatography, partition column chromatography, gel filtration, dialysis, precipitation, crystallization, etc.

[0053] In the manufacturing method of this embodiment, the protein encoded by the g5141 gene, the g5151a gene, or their variant genes is also considered as a purified substance. Protein purification can be performed alone or in appropriate combinations using affinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography, gel filtration chromatography, reversed-phase chromatography, etc. Furthermore, since the protein encoded by the g5141 gene, the g5151a gene, or their variant genes contains a tag, affinity chromatography utilizing the tag can be performed. Known tags can be used as the tag, for example, His tags, FLAG tags, MYC tags, HA tags, V5 tags, etc.

[0054] Step (a) of obtaining PF1378A by contacting the protein encoded by the g5141 gene or its variant with PF1378B can be carried out in a suitable reaction solution. The reaction solution may be, for example, a buffer solution adjusted to an appropriate pH and salt concentration. In the above reaction solution, PF1378A can be obtained by contacting the protein encoded by the g5141 gene or its variant with PF1378B.

[0055] The pH of the above reaction solution can be 4.0 to 9.0. Furthermore, the concentration of PF1378B in the above reaction solution can be 30 μM to 100 mM. Additionally, the concentration of the protein encoded by the g5141 gene or its variant can be 3 nM to 100 μM. Furthermore, the above reaction can be carried out at 15°C to 50°C. Furthermore, the reaction time can be, for example, 0.5 hours to 400 hours.

[0056] Furthermore, step (b) of obtaining PF1378B by contacting the protein encoded by the g5151a gene or its variant with PF1378C can be carried out in a suitable reaction solution. Such a reaction solution could be, for example, a buffer solution adjusted to an appropriate pH and salt concentration. In this reaction solution, PF1378B can be obtained by contacting the protein encoded by the g5151a gene or its variant with PF1378C.

[0057] The pH of the above reaction solution can be 4.0 to 9.0. Furthermore, the concentration of PF1378C in the above reaction solution can be 30 μM to 100 mM. Additionally, the concentration of the protein encoded by the g5151a gene or its variant can be 3 nM to 100 μM. Furthermore, the above reaction can be carried out at 15°C to 50°C. Furthermore, the reaction time can be, for example, 0.5 hours to 400 hours.

[0058] In the manufacturing method of this embodiment, step (a) of contacting the protein encoded by the g5141 gene or its variant gene with PF1378B to obtain PF1378A can also be carried out inside the cell of a microorganism.

[0059] In this case, PF1378B can be obtained through biosynthesis within the cell of the microorganism. Moreover, the biosynthesis of PF1378B and the conversion to PF1378A can be carried out continuously within the cell of the same microorganism.

[0060] Alternatively, step (b) of contacting the protein encoded by the g5151a gene or its variant with PF1378C to obtain PF1378B can also be carried out inside the cell of a microorganism.

[0061] In this case, PF1378C can be obtained through biosynthesis within the microbial cell. Furthermore, the biosynthesis of PF1378C and its conversion to PF1378B can be carried out continuously within the same microbial cell. Similarly, the conversion of PF1378B to PF1378A can also be carried out continuously within the same microbial cell.

[0062] The microorganism can be Aspergillus aculeatinus PF1378, or any other microorganism. Examples of microorganisms include actinomycetes, Escherichia coli, Bacillus subtilis, yeasts, and filamentous fungi.

[0063] In this case, PF1378B is synthesized within the microbial cells through microbial culture and then converted into PF1378A. Alternatively, PF1378C is synthesized within the microbial cells and converted into PF1378B, which in turn is converted into PF1378A.

[0064] The culture conditions for microorganisms can be appropriately selected based on the specific microorganisms used. Specific culture methods include, for example, solid-state culture under aerobic conditions, shaking culture in liquid media, aerated and stirred culture, and submerged aerobic culture. Suitable culture temperatures range from 15°C to 40°C. Although these temperatures vary depending on the microorganisms used, under any culture conditions, the accumulation of PF1378A typically reaches its peak within 2 to 10 days. Plant cells can also be used instead of microorganisms.

[0065] The manufacturing method of this embodiment can yield a composition containing PF1378A and PF1378B, or a composition containing PF1378A, PF1378B, and PF1378C. In the examples shown below, PF1378C is converted to PF1378B in the presence of the protein encoded by the g5151a gene or its variant, and sometimes PF1378C is almost undetectable.

[0066] The obtained PF1378A can be purified. The purification method is the same as that for PF1378B or PF1378C mentioned above. For example, solvent extraction, ion exchange resin method, adsorption column chromatography, partition column chromatography, gel filtration, dialysis, precipitation, crystallization and other methods can be carried out individually or in appropriate combinations.

[0067] [protein] In one embodiment, the present invention provides a protein composed of the amino acid sequence described in Serial No. 2. The protein composed of the amino acid sequence described in Serial No. 2 is a novel protein discovered by the inventors. As described above, PF1378A can be manufactured using the protein of this embodiment from PF1378B.

[0068] The protein in this embodiment can be a non-natural protein, or it can have a peptide tag for purification attached to its N-terminus or C-terminus, for example. There are no particular limitations on the peptide tag; examples include histidine tags, FLAG tags, and MYC tags.

[0069] In one embodiment, the present invention provides a variant protein comprising an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology with respect to the amino acid sequence described in Serial No. 2, and having the activity of converting PF1378B to PF1378A. As described above, PF1378A can be generated from PF1378B using the protein of this embodiment.

[0070] In one embodiment, the present invention provides a protein composed of the amino acid sequence described in Serial No. 7. The protein composed of the amino acid sequence described in Serial No. 7 is a novel protein discovered by the inventors. As described above, PF1378B can be manufactured using the protein of this embodiment from PF1378C.

[0071] The protein in this embodiment can be a non-natural protein, or it can have a peptide tag for purification attached to its N-terminus or C-terminus, for example. Regarding the peptide tag, the same applies as described above.

[0072] In one embodiment, the present invention provides a variant protein comprising an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology with respect to the amino acid sequence described in Serial No. 7, and having the activity of converting PF1378C to PF1378B. As described above, PF1378B can be generated from PF1378C using the protein of this embodiment.

[0073] [Nucleic Acid] (The nucleic acid encoding the g5141 gene or its variant) In one embodiment, the present invention provides a nucleic acid encoding the g5141 gene or a variant thereof. The cDNA of the g5141 gene has the base sequence described in Serial Number 1, and the cDNA of the variant gene has a base sequence with more than 70% sequence homology to the base sequence described in Serial Number 1. Furthermore, the protein encoded by the variant gene has the activity of converting PF1378B to PF1378A. The nucleic acid in this embodiment can be a non-natural nucleic acid.

[0074] In the nucleic acid of this embodiment, the g5141 gene and its variant genes are the same as described above. The variant gene can be a gene that has a base sequence with 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology to the base sequence described in Serial Number 1, and the protein encoded by the variant gene has the activity of converting PF1378B to PF1378A.

[0075] The nucleic acid in this embodiment can be in the form of a nucleic acid fragment or a vector. That is, the nucleic acid in this embodiment can also be a vector containing nucleic acid encoding the g5141 gene or its variant gene. The vector can be a virus, a plasmid, a fosmid, or a cosmid. More specifically, for example, when the host is *Escherichia coli*, it can be a bacteriophage of the λ phage line, or a plasmid of the pBR or pUC line. When the host is *Bacillus subtilis*, it can be a plasmid of the pUB line. When the host is yeast, it can be a plasmid of the YEp, YRp, YCp, or YIp line.

[0076] The nucleic acid in this embodiment preferably includes selection markers for screening transformants. Examples of selection markers include antibiotic resistance genes and genes that complement nutritional requirements. More specifically, when the host is bacteria, examples include ampicillin resistance genes, kanamycin resistance genes, and tetracycline resistance genes. When the host is yeast, examples include tryptophan biosynthesis genes (TRP1), uracil biosynthesis genes (URA3), and leucine biosynthesis genes (LEU2). When the host is filamentous fungi, examples include hygromycin resistance genes, diammonium phosphate resistance genes, bleomycin resistance genes, amoxicillin resistance genes, pyrithionein genes, and oligomycin resistance genes. When the host is a plant, examples include kanamycin resistance genes and diammonium phosphate resistance genes.

[0077] Nucleic acids can also serve as transcriptional or translational regulatory signals required for gene expression. Examples of such signals include promoters, transcription initiation signals, ribosome binding sites, translation stop signals, and transcription termination signals.

[0078] Examples of promoters used as promoters in the host *E. coli* include the lactose operon promoter and the tryptophan operon promoter. Examples of promoters used as promoters as the host are alcohol dehydrogenase gene promoters, acid phosphatase gene promoters, galactose assimilation gene promoters, and glyceraldehyde-3-phosphate dehydrogenase promoters. Examples of promoters used as promoters as the host are filamentous fungi, such as α-amylase gene promoters, glucosylamylase gene promoters, translation elongation factor 1-α gene promoters, and enolase gene promoters. Examples of promoters used as promoters as the host are plants, such as the CaMV 35S RNA promoter, the CaMV 19S RNA promoter, and the carmine synthase gene promoter.

[0079] (Nucleic acid encoding the g5151a gene or its variant) In one embodiment, the present invention provides a nucleic acid encoding the g5151a gene or a variant thereof, wherein the cDNA of the g5151a gene has the base sequence described in Serial No. 6, the cDNA of the variant gene has a base sequence with more than 70% sequence homology to the base sequence described in Serial No. 6, and the protein encoded by the variant gene has the activity of converting PF1378C to PF1378B. The nucleic acid in this embodiment may be a non-natural nucleic acid.

[0080] In the nucleic acid of this embodiment, the g5151a gene and its variant are the same as described above. The variant can be a base sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence homology to the base sequence described in Serial No. 6, and the protein encoded by the variant has the activity of converting PF1378C to PF1378B.

[0081] The nucleic acid in this embodiment can be in the form of a nucleic acid fragment or a vector. That is, the nucleic acid in this embodiment can also be a vector containing nucleic acid encoding the g5151a gene or a variant thereof. Regarding the vector, the same applies as described above.

[0082] The nucleic acid in this embodiment preferably includes a selection marker for screening transformants. The same applies to the selection marker described above.

[0083] Nucleic acids can also contain transcriptional or translational regulatory signals required for gene expression. The same applies to transcriptional and translational regulatory signals as described above.

[0084] [Transformation] (Transformed organisms containing nucleic acids encoding the g5141 gene or its variants) In one embodiment, the present invention provides a transformant in which nucleic acid encoding the g5141 gene or a variant thereof is introduced. The transformant of this embodiment can be obtained by introducing a nucleic acid fragment into a host using homologous recombination, or by introducing a vector into the host. Examples of hosts include actinomycetes, Escherichia coli, Bacillus subtilis, yeast, filamentous fungi, and plants. Regarding the nucleic acid, as described above, only an appropriate nucleic acid can be selected according to the host.

[0085] As a method for introducing nucleic acids into a host, any appropriate method can be selected based on the form of the nucleic acid and the host. Examples include conjugation transfer, phage transduction, calcium ion method, lithium ion method, electroporation method, PEG method, Agrobacterium method, and gene gun method.

[0086] The transformant of this embodiment can be used, for example, as a storage medium (vector) for the g5141 gene or its variant gene.

[0087] Alternatively, the transformant of this embodiment can express the protein encoded by the g5141 gene or its variant within its cells. Therefore, the transformant of this embodiment can be used for the conversion of PF1378B to PF1378A.

[0088] Furthermore, since the transformant of this embodiment is capable of biosynthesizing PF1378B, by culturing the transformant of this embodiment, the biosynthesis of PF1378B and its conversion to PF1378A can be performed to produce PF1378A. The culturing method of the transformant and the purification of the obtained PF1378A are the same as described above.

[0089] (Transformed organism containing nucleic acid encoding the g5151a gene or its variant) In one embodiment, the present invention provides a transformant having nucleic acid encoding the g5151a gene or a variant thereof introduced therein. The transformant of this embodiment can be obtained by introducing a nucleic acid fragment into a host using homologous recombination, or by introducing a vector into the host. The host and the method of introducing the nucleic acid into the host are the same as described above.

[0090] The transformant of this embodiment can be used, for example, as a storage medium (vector) for the g5151a gene or its variant gene.

[0091] Alternatively, the transformant of this embodiment can express the protein encoded by the g5151a gene or its variant within its cells. Therefore, the transformant of this embodiment can be used for the conversion of PF1378C to PF1378B.

[0092] Furthermore, since the transformant of this embodiment is capable of biosynthesizing PF1378C, by culturing the transformant of this embodiment, the biosynthesis of PF1378C and its conversion to PF1378B can be carried out.

[0093] Furthermore, by introducing nucleic acid encoding the g5141 gene or a variant thereof into the transformant of this embodiment, PF1378B can be converted into PF1378A, thereby producing PF1378A. The culture method of the transformant and the purification of the obtained PF1378A are the same as described above.

[0094] [Example] The present invention will then be illustrated with embodiments and described in further detail, but the invention is not limited to the following embodiments.

[0095] [Experimental Example 1] (Preparation of a non-homologous end-binding defective strain of Aspergillus niger PF1378) The whole genome of *Aspergillus niger* PF1378 was analyzed. Based on the whole genome analysis data, a homolog of ku70 (g6418) was identified. It is known that the ku70 homolog (g6418) is involved in the non-homologous end binding of *Aspergillus oryzae*. The base sequence of g6418 is shown in sequence number 4. Therefore, a hygromycin resistance gene was inserted into g6418 to create a g6418 knockout strain.

[0096] A gene fragment consisting of the 5' upstream fragment of g6418, an expression construct of the hygromycin resistance gene, and the 3' downstream fragment of g6418 was prepared sequentially. The resulting gene fragment was then introduced into *Aspergillus acuminata* PF1378 via protoplast-PEG method. The transformants were then cultured on Czapek-Dox agar medium containing 25 μg / mL hygromycin to screen for target transformants. The transformant with the ku70 homolog destroyed was named *Aspergillus acuminata* PF1378 Δku70.

[0097] [Experimental Example 2] (Preparation of uracil-dependent Aspergillus niger PF1378 Δku70) Based on the whole-genome analysis data of Aspergillus niger PF1378, a homolog (g3123) of the enzyme gene pyrG, which constitutes the uracil biosynthetic pathway in Aspergillus oryzae, was identified. The base sequence of g3123 is shown in SEQ ID NO: 5. Therefore, the pyridine thiamine resistance gene of Aspergillus oryzae was inserted into g3123 as a selection marker to create a uracil-demanding Aspergillus niger PF1378 Δku70.

[0098] A gene fragment consisting of the 5' upstream fragment of g3123, an expression construct of the pyrithione resistance gene, and the 3' downstream fragment of g3123 was prepared sequentially. The resulting gene fragment was then introduced into *Aspergillus acuminata* PF1378 Δku70 via protoplast-PEG method. Target transformants were then screened using Czapek-Dox agar medium containing 1 μg / mL pyrithione hydrobromide, 5 mM uridine, and 10 mM uracil. The obtained pyrithione resistance transformant, i.e., the uracil-demanding transformant, was named *Aspergillus acuminata* PF1378 Δku70 ΔpyrG.

[0099] [Experiment Example 3] (Introduction of Cre / loxP labeling cycle into Aspergillus niger PF1378 Δku70 ΔpyrG) A Cre / loxP marker cycle system with the pyrG gene from Aspergillus oryzae as the selectable marker was introduced into the pyramine resistance gene site of Aspergillus oryzae PF1378 Δku70 ΔpyrG obtained in Experiment 2.

[0100] A gene fragment was prepared sequentially, comprising the 5' upstream fragment of g3123, the lox66 sequence, the pyrG gene from *Aspergillus oryzae*, the lox71 sequence, the promoter region of the xylanase gene from *Aspergillus oryzae*, the coding region of Cre, the terminator region of the α-glucosidase gene from *Aspergillus oryzae*, and the 3' downstream fragment of g3123. The obtained gene fragment was then introduced into *Aspergillus niger* PF1378 Δku70 ΔpyrG using the protoplast-PEG method. Target transformants were then screened using Czapek-Dox agar medium.

[0101] The strain in which the pyridine thioamine resistance gene of Aspergillus PF1378 Δku70 ΔpyrG was replaced with the pyrG gene from Aspergillus oryzae and the Cre / loxP marker cassette was named Aspergillus PF1378 Δku70 Cre (A. aculeatinus PF1378 Δku70 Cre).

[0102] [Experiment Example 4] (Removal of the pyrG gene from Aspergillus oryzae from Aspergillus spicata PF1378 Δku70 Cre) The *Aspergillus aculeatinus* PF1378 Δku70 Cre strain prepared in Experiment 3 was cultured in Czapek-Dox medium containing 5 mM uridine, 10 mM uracil, and 1 mg / mL 5-fluoroorotic acid with 2% xylose as the carbon source to induce a Cre / loxP labeling cycle, thereby screening for strains that had the pyrG gene removed from *Aspergillus oryzae*. The resulting strain with the pyrG gene removed from *Aspergillus oryzae* was named *Aspergillus aculeatinus* PF1378 Δku70 Cre [pyrG-] (*A. aculeatinus* PF1378Δku70 Cre [pyrG-]).

[0103] [Experiment Example 5] (Removal of the g5141 gene from Aspergillus niger PF1378 Δku70 Cre [pyrG-]) Based on the whole-genome analysis data of Aspergillus niger PF1378, the g5141 gene was confirmed. The cDNA sequence of the g5141 gene is shown in Serial No. 1. The amino acid sequence of the protein encoded by the g5141 gene is shown in Serial No. 2. The genomic DNA sequence of the g5141 gene is shown in Serial No. 3.

[0104] Then, the g3123 gene, which is the pyrG gene of Aspergillus niger PF1378, was inserted into the g5141 locus to create a knockout strain of g5141.

[0105] A gene fragment was prepared comprising the 5' upstream fragment of g5141, the g3123 region of the pyrG gene (as in PF1378), and the 3' downstream fragment of g5141. The resulting gene fragment was then introduced into *Aspergillus acuminata* PF1378 Δku70 Cre [pyrG-] using the protoplast-PEG method. Target transformants were then screened using Czapek-Dox agar medium. The resulting g5141-deficient strain was named *Aspergillus acuminata* PF1378 Δku70 Cre Δg5141.

[0106] [Experiment Example 6] (Removal of the g5151a gene from Aspergillus niger PF1378 Δku70 Cre [pyrG-]) Based on the whole genome analysis data of Aspergillus niger PF1378, the g5151a gene was confirmed. The base sequence of the cDNA of the g5151a gene is shown in sequence number 6. The amino acid sequence of the protein encoded by the g5151a gene is shown in sequence number 7. The base sequence of the genomic DNA of the g5151a gene is shown in sequence number 8.

[0107] Then, the g3123 gene, which is the pyrG gene of Aspergillus niger PF1378, was inserted into the g5151a locus to create a g5151a knockout strain.

[0108] A gene fragment was prepared comprising the 5' upstream fragment of g5151a, the g3123 region of the pyrG gene (as in PF1378), and the 3' downstream fragment of g5151a. The resulting gene fragment was then introduced into *Aspergillus acuminata* PF1378 Δku70 Cre [pyrG-] using the protoplast-PEG method. Target transformants were then screened using Czapek-Dox agar medium. The resulting g5151a-deficient strain was named *Aspergillus acuminata* PF1378 Δku70 Cre Δg5151a.

[0109] [Experiment Example 7] (Study on the production capacity of PF1378A and PF1378B of Aspergillus niger PF1378 Δku70 Cre Δg5141) The production capacity of PF1378A and PF1378B in Aspergillus niger PF1378 Δku70 Cre Δg5141 was studied.

[0110] Using potato dextrose agar, Aspergillus niger PF1378 and Aspergillus niger PF1378 Δku70 Cre Δg5141 were cultured separately, and conidia were recovered. Then, the conidia suspended in 0.01% Tween 20 aqueous solution were cultured to form 4 × 10⁻⁶ cells / mL. 5 The conidia were diluted at a rate of 1 / mL to prepare a conidial suspension.

[0111] Brown rice (Akita Komachi) soaked overnight was autoclaved at 121°C for 20 minutes to prepare a rice culture medium. 5g of the prepared rice culture medium was transferred to a bioreactor tube (TPP(R) TubeSpin 50mL) and inoculated with 500μL of conidial suspension. The rice culture medium inoculated with conidial suspension was then incubated statically at 25°C for 7 days. After 7 days, 10mL of 67% acetone aqueous solution was added. Following addition, the mixture was thoroughly stirred for 1 hour using a shaker, and then centrifuged at 4°C, 10,000×g for 60 minutes. The resulting supernatant was used as a sample, and PF1378A and PF1378B were quantified using HPLC. The experiment was conducted with n=5.

[0112] The quantitative results for PF1378A are shown in Table 1 below, and the quantitative results for PF1378B are shown in Table 2 below. The results showed that both PF1378A and PF1378B were produced in *Aspergillus niger* PF1378. On the other hand, while PF1378B was detected in *Aspergillus niger* PF1378Δku70 Cre Δg5141, PF1378A was not detected. Therefore, it is confirmed that the protein encoded by the g5141 gene is involved in the conversion from PF1378B to PF1378A. That is, it is clarified that transformants obtained by introducing the g5141 gene into microorganisms that do not possess the g5141 gene but produce PF1378B, or transformants obtained by introducing the g5141 gene into microorganisms capable of externally conferring PF1378B, can produce PF1378A.

[0113] [Table 1]

[0114] [Table 2]

[0115] [Experiment Example 8] (Study on the production capacity of PF1378A, PF1378B and PF1378C of Aspergillus niger PF1378 Δku70 Cre Δg5151a) The production capacity of PF1378A, PF1378B and PF1378C in Aspergillus niger PF1378 Δku70 Cre Δg5151a was studied.

[0116] Aspergillus niger PF1378 and Aspergillus niger PF1378 Δku70 Cre Δg5151a were cultured on potato dextrose agar, and conidia were recovered. Then, the conidia suspended in 0.01% Tween 20 aqueous solution were cultured to form 4 × 10⁻⁶ cells / mL. 5The conidia were diluted at a rate of 1 / mL to prepare a conidial suspension.

[0117] Barley (round barley from Saga Prefecture) soaked in water for 2 hours was autoclaved at 121°C for 20 minutes to prepare barley culture medium. 5g of the prepared barley culture medium was transferred to a bioreactor tube (TPP(R) TubeSpin 50mL) and inoculated with 500μL of conidial suspension. The barley culture medium inoculated with conidial suspension was then incubated statically at 25°C for 7 days. 10mL of 67% acetone aqueous solution was added after inoculation. The mixture was stirred thoroughly for 1 hour using a shaker and then centrifuged at 4°C, 10,000×g for 60 minutes. The supernatant was dried and solidified using a centrifuge, then dissolved in an equal volume of methanol. The resulting solution was used as a sample, and PF1378A, PF1378B, and PF1378C were measured using LCMS.

[0118] The quantitative results for PF1378A, PF1378B, and PF1378C are shown in Table 3 below. In Table 3, "ND" indicates below the detection limit. The peak area at m / z 374 is set as the production yield of PF1378A, the peak area at m / z 360 as the production yield of PF1378B, and the peak area at m / z 346 as the production yield of PF1378C. The production yield is expressed as a relative value with the production yield of PF1378A and PF1378B in the *Aspergillus niger* PF1378 strain set to 100. Furthermore, the production yield of PF1378C is expressed as a relative value with the production yield of PF1378B in the *Aspergillus niger* PF1378 strain set to 100.

[0119] As a result, both PF1378A and PF1378B were detected in *Aspergillus niger* PF1378. On the other hand, PF1378C was detected in *Aspergillus niger* PF1378 Δku70 Cre Δg5151a, but PF1378A and PF1378B were not detected. This confirms that the protein encoded by the g5151a gene is involved in the conversion from PF1378C to PF1378B. In other words, it is clear that transformants created by introducing the g5151a gene into microorganisms that do not possess the g5151a gene but produce PF1378C, or transformants created by introducing the g5151a gene into microorganisms capable of externally conferring PF1378C, can produce PF1378B.

[0120] [Table 3]

[0121] [Experiment Example 9] (Removing the g5141 gene, removing the pyrG gene, and introducing the g5141 gene separately from Aspergillus niger PF1378 Δku70 Cre [pyrG-]) A g3123 gene, acting as the pyrG gene of Aspergillus niger PF1378, was inserted into the g5141 locus to create a g5141 knockout strain. The design was intended to remove the pyrG gene after the knockout strain was created. After the knockout strain was created, the pyrG gene was removed, and finally, the pyrG gene was reintroduced as a selection marker in a stable state expressing g5141.

[0122] A gene fragment was prepared comprising the 5' upstream fragment of g5141, the lox66 sequence, the g3123 gene (which serves as the pyrG gene for PF1378), the lox71 sequence, and the 3' downstream fragment of g5141. The obtained gene fragment was then introduced into *Aspergillus acuminata* PF1378 Δku70 Cre [pyrG-] using the protoplast-PEG method. Target transformants were then screened using Czapek-Dox agar medium. The strain in which both the g5141 gene and the pyrG gene were removed was named *Aspergillus acuminata* PF1378 Δku70 Cre Δg5141::lox66::pyrG::lox71 (*A. aculeatinus PF1378 Δku70 Cre Δg5141::lox66::pyrG::lox71).

[0123] Then, *Aspergillus acuminata* PF1378 Δku70 Cre Δg5141::lox66::pyrG::lox71 was cultured in Czapek-Dox medium containing 5 mM uridine, 10 mM uracil, and 1 mg / mL 5-fluoroorotic acid with 2% xylose as the carbon source to induce a Cre / loxP labeling cycle, thereby screening for strains with the pyrG gene removed. The resulting strain with the pyrG gene removed from PF1378 was named *Aspergillus acuminata* PF1378 Δku70 Cre Δg5141 [pyrG-] (*A. aculeatinus PF1378 Δku70 Cre Δg5141 [pyrG-]).

[0124] Based on the whole-genome analysis data of *Aspergillus niger* PF1378, the existence of a homolog (g4093) of the translation elongation factor 1-α gene, i.e., tef1, from *Aspergillus oryzae* was confirmed. The 1012 bp promoter sequence of g4093 is shown in SEQ ID NO: 9. A strain was constructed in *Aspergillus niger* PF1378 Δku70 Cre Δg5141 [pyrG-] to express g5141 via the promoter of g4093. A gene fragment was prepared comprising, sequentially, the 5' upstream fragment of g5141, the g3123 gene (as the pyrG gene of PF1378), the promoter region of the g4093 gene, the coding region of g5141 (SEQ ID NO: 3), and the 3' downstream fragment of g5141. The resulting gene fragment was then introduced into *Aspergillus niger* PF1378 Δku70 Cre Δg5141 [pyrG-] using the protoplast-PEG method. Then, the target transformants were screened using Czapek-Dox agar medium. The strain in which the obtained g5141 gene was separately introduced via the g4093 promoter was named *A. aculeatinus* PF1378Δku70 Cre Δg5141::pyrG::Pg4093::g5141.

[0125] [Experiment Example 10] (Study on the production capacity of PF1378A and PF1378B of Aspergillus niger PF1378 Δku70 Cre Δg5141::pyrG::Pg4093::g5141) The production capacity of PF1378A and PF1378B of the strain of Aspergillus niger PF1378 Δku70 Cre Δg5141 [pyrG-] prepared in Experimental Example 9, in which g5141 was separately introduced, was investigated.

[0126] Barley (round barley from Saga Prefecture) soaked in water for 2 hours was autoclaved at 121°C for 20 minutes to prepare barley culture medium. 5g of the prepared barley culture medium was transferred to a bioreactor tube (TPP(R) TubeSpin 50mL) and inoculated with 500μL of conidial suspension. The barley culture medium inoculated with conidial suspension was then incubated statically at 25°C for 7 days, after which 10mL of 67% acetone aqueous solution was added. After addition, the mixture was thoroughly stirred for 1 hour using a shaker, followed by centrifugation at 4°C, 10,000×g for 60 minutes. The resulting supernatant was used as a sample, and PF1378A and PF1378B were measured using LCMS. The experiment was conducted with n=2.

[0127] The quantitative results for PF1378A are shown in Table 4 below, and the quantitative results for PF1378B are shown in Table 5 below. The results showed that both PF1378A and PF1378B were detected in *Aspergillus niger* PF1378 Δku70 Cre Δg5141::pyrG::Pg4093::g5141. As shown in Example 7, *Aspergillus niger* PF1378 Δku70 Cre Δg5141 did not produce PF1378A; therefore, this result further supports the conclusion that the protein encoded by the g5141 gene is involved in the conversion from PF1378B to PF1378A. That is, this further supports the conclusion that transformants created by introducing the g5141 gene into microorganisms that do not possess the g5141 gene and produce PF1378B, or transformants created by introducing the g5141 gene into microorganisms that can externally impart PF1378B, can produce PF1378A.

[0128] [Table 4]

[0129] [Table 5]

[0130] Industrial applicability According to the present invention, a manufacturing technique for PF1378A can be provided.

Claims

1. A manufacturing method, which is a method for manufacturing PF1378A, comprising step (a) of contacting one or more proteins selected from the group consisting of (1) to (4) below with PF1378B to obtain PF1378A. (1) A protein composed of the amino acid sequence recorded in sequence number 2, (2) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 2, and having the activity of converting PF1378B to PF1378A. (3) The protein encoded by the base sequence recorded in sequence number 1, (4) A protein encoded by a base sequence having more than 70% sequence homology with the base sequence described in sequence number 1 and having the activity of converting PF1378B to PF1378A.

2. The manufacturing method according to claim 1, wherein, The process (a) is carried out inside the cells of a microorganism.

3. The manufacturing method according to claim 1 or 2, wherein, Before step (a), step (b) further includes contacting PF1378C with one or more proteins selected from the group consisting of (5) to (8) below to obtain PF1378B. (5) Proteins composed of the amino acid sequence recorded in sequence number 7, (6) A protein consisting of an amino acid sequence having more than 70% sequence homology to the amino acid sequence described in sequence number 7, and having the activity of converting PF1378C to PF1378B. (7) The protein encoded by the base sequence recorded in sequence number 6, (8) A protein encoded by a base sequence having more than 70% sequence homology with the base sequence described in sequence number 6 and having the activity of converting PF1378C to PF1378B.

4. The manufacturing method according to claim 3, wherein, The process (b) is carried out inside the cells of microorganisms.

5. A protein comprising the amino acid sequence described in Serial No. 2, or comprising an amino acid sequence having more than 70% sequence homology with respect to the amino acid sequence described in Serial No. 2, and having the activity of converting PF1378B to PF1378A.

6. A protein comprising the amino acid sequence described in Serial No. 7, or comprising an amino acid sequence having more than 70% sequence homology with respect to the amino acid sequence described in Serial No. 7, and having the activity of converting PF1378C to PF1378B.

7. A nucleic acid encoding the protein of claim 5.

8. The nucleic acid according to claim 7, comprising the base sequence described in sequence number 1, or comprising a base sequence having more than 70% sequence homology with respect to the base sequence described in sequence number 1, and encoding a protein having the activity of converting PF1378B to PF1378A.

9. A nucleic acid encoding the protein of claim 6.

10. The nucleic acid according to claim 9, comprising the base sequence described in sequence number 6, or comprising a base sequence having more than 70% sequence homology with respect to the base sequence described in sequence number 6, and encoding a protein having the activity of converting PF1378C to PF1378B.

11. A transformant, comprising the nucleic acid of claim 7 or 8.

12. A transformant, comprising the nucleic acid of claim 9 or 10.

Citation Information

Patent Citations

  • Insecticide for agricultural / horticultural use comprising 16-ketoaspergillimide as the active ingredient

    WO2008156165A1

  • Composition to control harmful organisms that contains 16-keto aspergillimide

    WO2010071218A1

  • 16-ketoaspergillimide and pest exterminating agent comprising the same as active ingredient

    WO2010071219A1